Pravastatin sodium

普伐他汀钠

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NamePravastatin sodium
Drug Alias NameEptastatin sodium普伐司他汀钠普伐他丁钠pravastatinumpravastatine +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsIschemic StrokeHypertriglyceridemiaHypercholesterolemia +[23] 
Global Approved IndicationsHypertriglyceridemiaHypercholesterolemiaDyslipidemias
Approved Indications in ChinaHypertriglyceridemiaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryUnited States
Original Approved Date1991/10/31
Country/TerritoryCanadaUnited StatesSouth Africa +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversitat Autonoma De BarcelonaInstitut Regional Du Cancer De MontpellierJohns Hopkins University +[6] 
Inactive CompaniesNational Institutes Of HealthArkansas Children'S Research InstitutePontificia Universidad Catolica De Chile +[16] 
Active IndicationsHypertriglyceridemiaHypercholesterolemiaDyslipidemias +[8] 
Inactive IndicationsIschemic StrokeHyperlipidemiasMucocutaneous Lymph Node Syndrome +[15] 

Other Information

ATC CodeC10AA03
Related LinksWikipediaDrugBankKEGG